Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas

Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas

Genetically modified T-cell immunotherapies are revolutionizing the therapeutic options for hematological malignancies, especially those of B-cell origin. Impressive efficacies of CD19-directed chimeric antigen receptor (CAR)-T therapy have been reported in refractory/relapsed (R/R) B-cell non-Hodgk...

Full description

Bibliographic Details
Main Authors: Hao Xu, Ningwen Li, Gaoxiang Wang, Yang Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-03-01
Series:Frontiers in Immunology
Subjects:
biomarker
CAR-T therapy
B-cell lymphoma
refractory/relapse
efficacy
resistance
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1110028/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1110028/full

Similar Items